Cancer Medicine (Oct 2024)

Preoperative Serum Glycan Levels Reflect Progression of Patients With Hepatocellular Carcinoma

  • Sheng‐Sheng Liu,
  • Lei Ye,
  • Qing‐Qing Dai,
  • Yi Gao,
  • Guang‐Hou Chen,
  • Hong‐Chuan Zhao,
  • Wei‐Dong Du

DOI
https://doi.org/10.1002/cam4.70285
Journal volume & issue
Vol. 13, no. 19
pp. n/a – n/a

Abstract

Read online

ABSTRACT Background Abnormal glycosylation is associated with tumors. The clinical value of serum glycans in assessing progression of hepatocellular carcinoma (HCC) patients remains a challenge. Methods A study dynamically comparing levels of fifteen lectin‐specific glycans between preoperative and postoperative serum of 65 HCC patients was conducted via lectin biochip technology. Multivariable logistic regression analysis was used to address associations between serum glycan levels and clinicopathological characteristics. Kaplan–Meier analysis was used to evaluate the impacts of serum glycan levels on overall survival (OS) and progression‐free survival (PFS) of the HCC patients. Results HCC patients presented significantly higher levels of the lectin‐specific glycans in preoperative serum than disease‐free individuals (p < 0.001 − p = 0.029), except ConA. The glycans in preoperative sera were significantly related to tumor size, pTNM, metastasis, BCLC stage, portal hypertension (PHT), and platelet count (PLT), respectively (p < 0.05). Multivariate logistic analyses indicated that tumor size and pTNM independently impact on glycan‐specific lectins either LTL, UEA‐I, VVL, NPL, WGA, PNA, MAL‐I, SNA, or PHA‐L (p = 0.003 − p = 0.044); BCLC stage and PLT were independent factors influencing the serum glycans recognizable DSA (p = 0.024) and SNA (p = 0.050), respectively. Surgical excision of tumor mass significantly reduced glycan levels in sera. Tumor differentiation, albumin, and ABO type significantly revealed independent influence on glycan‐specific lectins, such as RCA‐I (p = 0.024), VVL (p = 0.024), and Con A (p = 0.026) in the postoperative serum. HCC patients with high levels of VVL‐binding glycans significantly benefited from a longer OS time (p = 0.016, HR: 0.460, 95% CI: 0.237–0.892) and a better PFS time (p = 0.004; HR: 0.435, 95% CI: 0.237–0.799), respectively. Conclusion Serum glycans could reflect surgical outcomes in at‐risk patients and become valuable biomarkers in evaluating the progression of HCC patients.

Keywords